Evaluation of interim Dotatate-PET after two cycles of Peptide Receptor Radionuclide Therapy (PRRT) in neuroendocrine tumors (NET)

#3589

Introduction: Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE is a targeted radionuclide treatment for patients with neuroendocrine tumors (NET).

Aim(s): We aimed to evaluate the information provided by imaging with 68Ga-DOTATATE PET after two cycles of PRRT for prediction of early response.

Materials and methods: Ninety-three patients (47 women and 46 men, mean±SD: 62.9±10.7 years) with progressive, somatostatin receptor (SSR)-expressing NET were treated with 177Lu-DOTATATE. All patients had baseline DOTATATE-PET, interim imaging after two treatment cycles and upon completion of PRRT. RECIST and change in SSR-density were used to evaluate treatment response. Change in tumor marker chromogranin A was recorded.

Conference:

Presenting Author: Duan H

Authors: Duan H, Song H, Ferri V, Fisher G, Shaheen S,

Keywords: PRRT, NET, Dotatate, PET, early response, Pseudo-progression,